今日,加科思药业宣布,其自主研发的KRAS G12C抑制剂戈来雷塞(glecirasib,JAB-21822)注册性临床试验数据在《Nature Medicine》(影响因子58.7)发布,这是公司首次公开戈来雷塞治疗KRAS G12C突变的二线以及上肺癌患者的完整数据。关于最新披露研究数据这是一项在中国进行的,单药治疗KRASG12C 突变晚期实体瘤患者的 1/2 期开放标签研究。截至数据截止...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.